iBio Enters $15 Million Private Placement

DENVER, Colo., Mar 27, 2024 (247marketnews.com)- iBio, Inc. (NYSEA:IBIO) reported, after yesterday’s market close, that it entered into a private investment in public equity (“PIPE”) financing that is expected to generate approximately $15 million, before deducting placement agent fees and offering expenses, with institutional and accredited investors

the $2.85 purchase price represents a 148% premium to yesterday’s close  and the proceeds are expected to extend its operating plan cash runway through fiscal year 2025.

“We appreciate the support of this outstanding group of healthcare specialist investors that shares the vision of leveraging our cutting-edge AI/Machine learning platform to deliver best-in-class drugs,” said iBio’s Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D.

IBIO is trading at $1.84, up $0.69 (+60.00%), on 3.67M shares.

Its 52-week range is $1.0214 to $49.00. It has a big gap from early December to around the PIPI exercise price and gaps often tend to refill. This triggered our alerts in yesterday’s afterhours session and this morning’s premarket high is $2.29.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://www.247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.